BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weatherald J, Humbert M, Guignabert C, Montani D. Response to the article “Sorafenib as a potential strategy for refractory pulmonary arterial hypertension”. Pulmonary Pharmacology & Therapeutics 2017;45:11-2. [DOI: 10.1016/j.pupt.2017.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Jutant EM, Jaïs X, Girerd B, Savale L, Ghigna MR, Perros F, Mignard X, Jevnikar M, Bourlier D, Prevot G, Tromeur C, Bauer F, Bergot E, Dauphin C, Favrolt N, Traclet J, Soumagne T, De Groote P, Chabanne C, Magro P, Bertoletti L, Gueffet JP, Chaouat A, Goupil F, Moceri P, Borie R, Fadel E, Wolkenstein P, Brillet PY, Simonneau G, Sitbon O, Humbert M, Montani D. Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. Am J Respir Crit Care Med 2020;202:843-52. [PMID: 32437637 DOI: 10.1164/rccm.202001-0105OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
2 Sommer N, Ghofrani HA, Pak O, Bonnet S, Provencher S, Sitbon O, Rosenkranz S, Hoeper MM, Kiely DG. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol 2021;178:6-30. [PMID: 32034759 DOI: 10.1111/bph.15016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 58] [Article Influence: 24.5] [Reference Citation Analysis]
3 Jutant EM, Girerd B, Jaïs X, Savale L, O'Connell C, Perros F, Sitbon O, Humbert M, Montani D. Pulmonary hypertension associated with neurofibromatosis type 1. Eur Respir Rev 2018;27:180053. [PMID: 30158278 DOI: 10.1183/16000617.0053-2018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]